Patents by Inventor Peggy J. Farnham

Peggy J. Farnham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETABLE PROTEINS FOR EPIGENETIC MODIFICATION AND METHODS FOR USE THEREOF
    Publication number: 20190233805
    Abstract: Provided herein are fusion proteins comprising a catalytically inactive Cas9 domain and an effector domain. The fusion proteins of the present invention can be used to, for example, produce epigenetic modifications at target chromatin sites. Nucleic acids and expression vectors encoding the fusion proteins, as well as cells comprising the fusion proteins, are also provided herein.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 1, 2019
    Applicant: The Regents of the University of California
    Inventors: David J Segal, Henriette O'Geen, Joel P. Mackay, Peggy J. Farnham
  • Liver tumor marker sequences
    Patent number: 7220844
    Abstract: Novel polypeptides and nucleic acids that encode the polypeptides are disclosed. The polypeptides and nucleic acids are differentially expressed in liver tumors relative to expression in normal liver tissues. In humans, the nucleic acid sequence maps to a region of chromosome 9p.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: May 22, 2007
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peggy J. Farnham, Carrie R. Graveel
  • Liver tumor marker sequences
    Patent number: 7129328
    Abstract: Polypeptides whose expression is upregulated in liver tumor cells and cells from liver preneoplastic foci relative to expression in normal liver cells are disclosed as are polynucleotides that encode the polypeptides. In humans, the polynucleotide maps to a region of chromosome 15. The overexpression has also been confirmed in human liver, breast, colon and kidney cancer cell lines. It is believed that the polypeptides are overexpressed in tumor and preneoplastic cells in general.
    Type: Grant
    Filed: July 16, 2003
    Date of Patent: October 31, 2006
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peggy J. Farnham, Carrie R. Graveel, Sarah R. Harkins-Perry
  • Liver tumor marker sequences
    Publication number: 20040086916
    Abstract: Polypeptides whose expression is upregulated in liver tumor cells and cells from liver preneoplastic foci relative to expression in normal liver cells are disclosed as are polynucleotides that encode the polypeptides. In humans, the polynucleotide maps to a region of chromosome 15. The overexpression has also been confirmed in human liver, breast, colon and kidney cancer cell lines. It is believed that the polypeptides are overexpressed in tumor and preneoplastic cells in general.
    Type: Application
    Filed: July 16, 2003
    Publication date: May 6, 2004
    Inventors: Peggy J. Farnham, Carrie R. Graveel, Sarah R. Harkins-Perry
  • Liver tumor marker sequences
    Publication number: 20020115094
    Abstract: Novel polypeptides and nucleic acids that encode the polypeptides are disclosed. The polypeptides and nucleic acids are differentially expressed in liver tumors relative to expression in normal liver tissues. In humans, the nucleic acid sequence maps to a region of chromosome 9p.
    Type: Application
    Filed: December 14, 2001
    Publication date: August 22, 2002
    Inventors: Peggy J. Farnham, Carrie R. Graveel